The Court of Appeals (CA) has denied Sanofi Pasteur’s motion for reconsideration regarding its Dengvaxia dengue vaccine, upholding a previous decision that revoked the vaccine’s certificates of product registration (CPRs) in 2018.
The revocation followed Sanofi’s 2017 disclosure that Dengvaxia posed risks to individuals who had not previously contracted the virus, leading the Philippine government to halt its national vaccination program.
In a resolution dated September 20, the CA dismissed Sanofi’s petition for review, reaffirming the permanent revocation of the CPRs.
Associate Justice Eduardo Ramos Jr. noted that the arguments presented in the motion had already been deemed without merit.
As a result, the ban on Dengvaxia remains in effect.
Source: PhilNews24 | September 26, 2024
SANOFI’S DENGVAXIA APPEAL DISMISSED BY COURT OF APPEALS
Latest from News
The International Energy Agency announced it will release 271.7 million barrels of strategic oil reserves worldwide
Donald Trump called on U.S. allies to help secure the Strait of Hormuz after Iran disrupted
Women in the Philippines continue to face dangerous and unregulated abortion practices as strict laws banning
The Philippine Navy said it will continue regular patrols in the West Philippine Sea despite soaring
Alan Peter Cayetano urged Malacañang to establish a national contingency plan (NCP) to safeguard overseas Filipino